VESTAR INCREASES REVENUESVestar Inc. (NASDAQ:VSTR) of San Dimas, Calif., said itsrevenues shifted as a result of increased sales of its flagshipproduct, AmBisome, in 13 countries. AmBisome revenueaccounted for 84 percent of total 1990 revenues comparedwith less than 3 percent in 1989, when nearly all revenuescame from collaborative research arrangements rather thanproduct sales.

Fourth quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $1,859 $379 +390Net income (loss) (2,622) (2,142) -22Net income per share (loss) (.44) (.33) -33

Year ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $4,492 3,468 +30Net income (loss) (7,706) (7,595) -1Net income per share (loss) (1.23) (1.19) -3Outstanding shares 6,490 6,387 +2

LIPOSOME TECHNOLOGY DEEPENS NET LOSS

Liposome Technology Inc. (NASDAQ:LTIZ).of Menlo Park, Calif.,said its 11 percent increase in research and developmentexpenditures to almost $2 million for the quarter was due to anexpansion of the company's pre-clinical and clinical activities tocommercialize its priority products. Increased expenditures forpre-clinical and clinical studies accounted for the deeper netloss, the company said.

Fourth quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $102 $225 -55Net income (loss) (2,545) (1,745) -46Net income per share (loss) (.27) (.25) -8Outstanding shares 9,356 7,083 +32

Year ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $2,063 2,107 -2Net income (loss) (7,471) (7,286) -3Net income per share (loss) (.80) (1.04) +23Outstanding shares 9,348 7,009 +33

T CELL SCIENCES REPORTS NET LOSS

T Cell Sciences Inc. (NASDAQ:TCEL) of Cambridge, Mass., saidthat it received during last year's third quarter a one-time$900,000 payment in connection with the signing of a productdevelopment and marketing agreement with SmithKlineBeecham plc. for developing a complement blocker drug. Thispayment was responsible for higher revenues for last year'sthird quarter, the company said.

Third quarter ended Jan. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $2,830 3,628 -22Operating expenses 3,635 3,637 neg.Net income (loss) (805) (9) -8,844Net income per share (loss) (.08) -- n/aOutstanding shares 10,234 8,640 +18

SYNTEX EARNINGS UP 40 PERCENT

Syntex Corp. (NYSE:SYN) of Palo Alto, Calif., said second-quarterresults reflect increased sales of newer pharmaceuticalproducts worldwide and increased sales of Naprosyn andAnaprox in the United States.

Second quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues 444,100 342,700 +30Operating income 121,900 76,000 +60Net income (loss) 101,500 72,000 +41Net income per share (loss) .90 .64 +41Outstanding shares 112,300 111,800 neg.

INVESTMENTS BOOST U.S. BIOSCIENCE'S REVENUES

Revenues went up sixfold last year, to $3.5 million, as a resultof an increase in investment income following stock offerings inSeptember 1989 and February 1990 at U.S. Bioscience Inc.(AMEX:UBS) of West Conshohocken, Pa. Chairman and ChiefExecutive Officer Philip S. Schein said 1990 results wereconsistent with management's expectations and reflect thecompany's expanding drug research and developmentprograms.

Fourth quarter ended Dec. 31:

(Figures in thousands except per-share data)

1990 1989 Percent change

Revenues $1,407 310 +354Net income (loss) (1,281) (1,452) +12Net income per share (loss) (.08) (.11) +27Outstanding shares 16,932 12,692 +33

Year ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $3,453 $494 +599Net income (loss) (4,925) (5,743) +14Net income per share (loss) (.30) (.52) +42Outstanding shares 16,343 11,000 +49

COLLABORATIVE RESEARCH DEEPENS LOSS

Collaborative Research Inc. (NASDAQ:CRIC) of Bedford, Mass.,said the deeper net loss reflected a $665,000 contractsettlement gain from Sandoz in the same quarter the previousyear.

First quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $2,167 2,090 +4Operating income (loss) (884) (840) -5Net income (loss) (884) (185) -377Net income per share (loss) (.08) (.02) -300Outstanding shares 10,658 10,656 neg.

IMMUNOMEDICS REVENUES FALL, LOSS DEEPENS

Immunomedics Inc. (NASDAQ:IMMU) of Warren, N.J., said lowersecond-quarter revenues are attributable to a slowdown insales of in vitro products, particularly in Europe, expiration of afederal government grant for research completed in fiscal1990, and reduced interest income earned from cashequivalents and market securities.

Second quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $354 651 -46Net income (loss) (1,155) (886) -30Net income per share (loss) (.05) (.04) -25Outstanding shares 23,074 23,074 n/c

CISTRON REPORTS NET LOSS

Cistron Biotechnology Inc. (OTC:CIST) of Pine Brook, N.J.,attributed lower sales and earnings in the second quarter to adecrease in governmental agency purchases due to the delay inadopting the federal budget.

Second quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $231 271 -15Extraordinary credit -- 13 n/aNet income (loss) (10) 34 -129Net income per share (loss) (0.04) 0.16 -125Outstanding shares 25,017 21,325 +17

(c) 1997 American Health Consultants. All rights reserved.